Profile data is unavailable for this security.
About the company
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
- Revenue in INR (TTM)100.29bn
- Net income in INR24.85bn
- Incorporated1990
- Employees18.30k
- LocationDivi's Laboratories Ltd1-72/23(P)/Divis/303, Divi Towers, Cyber Hills, Gachibowli,HYDERABAD 500032IndiaIND
- Phone+91 4 023786300
- Fax+91 4 023786460
- Websitehttps://www.divislabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mankind Pharma Ltd | 138.42bn | 17.75bn | 859.42bn | 27.00k | 48.48 | -- | 32.10 | 6.21 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Zydus Lifesciences Ltd | 260.89bn | 49.38bn | 929.21bn | 27.92k | 18.81 | -- | 15.30 | 3.56 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Lupin Ltd | 247.51bn | 43.25bn | 1.00tn | 19.98k | 23.26 | 5.11 | 17.84 | 4.06 | 94.43 | 94.43 | 540.38 | 429.82 | 0.8393 | 1.25 | 4.34 | 12,388,350.00 | 14.74 | 4.53 | 21.74 | 7.16 | 71.70 | 59.70 | 17.57 | 5.95 | 1.32 | 110.56 | 0.2396 | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Dr Reddy's Laboratories Ltd | 346.82bn | 55.68bn | 1.06tn | 26.94k | 19.09 | -- | 14.20 | 3.06 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Cipla Ltd | 283.51bn | 45.46bn | 1.08tn | 30.31k | 23.86 | -- | 19.48 | 3.83 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Torrent Pharmaceuticals Ltd | 122.48bn | 21.40bn | 1.35tn | 16.11k | 63.22 | 16.01 | 45.93 | 11.05 | 63.23 | 63.23 | 361.86 | 249.64 | 0.8005 | 1.26 | 6.17 | 7,604,203.00 | 13.99 | 9.54 | 20.08 | 14.72 | 75.69 | 72.56 | 17.47 | 14.14 | 0.8352 | 14.67 | 0.2504 | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
| Divi's Laboratories Ltd | 100.29bn | 24.85bn | 1.62tn | 18.30k | 65.27 | 10.53 | 55.66 | 16.18 | 93.67 | 93.67 | 378.05 | 580.60 | 0.5945 | 1.20 | 4.18 | 5,480,328.00 | 14.73 | 15.81 | 16.18 | 17.33 | 60.79 | 55.90 | 24.78 | 25.82 | 3.71 | -- | 0.0058 | 35.19 | 19.31 | 11.65 | 36.94 | 9.74 | 3.98 | 13.40 |
| Holder | Shares | % Held |
|---|---|---|
| SBI Funds Management Ltd.as of 15 Jan 2026 | 12.11m | 4.56% |
| Life Insurance Corporation of India (Investment Portfolio)as of 16 Oct 2025 | 8.01m | 3.02% |
| GIC Pte Ltd. (Investment Management)as of 31 Mar 2025 | 6.01m | 2.26% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 4.94m | 1.86% |
| Axis Asset Management Co. Ltd.as of 15 Jan 2026 | 4.04m | 1.52% |
| Norges Bank Investment Managementas of 31 Mar 2025 | 3.51m | 1.32% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Dec 2025 | 3.45m | 1.30% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2025 | 3.14m | 1.18% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 2.94m | 1.11% |
| Wasatch Advisors LPas of 31 Dec 2025 | 2.24m | 0.84% |
